UroGen Pharma (URGN) Finance Lease Principal Payments Financing Activities — Quarterly & Annual

Screener

Finance Lease Principal Payments Financing Activities at other companies

SalesforceCRM

$130M-27.4%

REX American ResourcesREX

$62K—

TRV

Trevi Therapeutics, Inc.TRVI

$0-100%

Lithium AmericasLAC

$1.22M+1.7%

PhotronicsPLAB

$2.75K-99.8%

VestisVSTS

$9.52M+11.7%

Other financials

Income statement

Revenue$72.5M+199%

Net income-$14.4M+71.3%

Balance sheet

Cash & equivalents$79.1M-14.8%

Total debt$197.5M+55.0%

Total equity-$132.4M-41.8%

Total assets$252.6M+21.0%

Cash flow

Operating cash flow-$33.0M+17.1%

CapEx$60.0K-57.4%

Free cash flow-$33.1M+17.3%

Valuation

Market cap$2.29B+171%

Enterprise value$2.41B+174%

P/S12.1×+3.2×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-51.7%-21.0pp

FCF margin-84.3%-22.2pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio3.8×-0.3×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept urgn:FinanceLeasePrincipalPaymentsFinancingActivities.

The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026. Open the filing →

Filed: Aug 5, 2026, 8:05 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001437749-26-025794

FAQ

What is UroGen Pharma's finance lease principal payments financing activities?: UroGen Pharma (URGN) reported finance lease principal payments financing activities of $387K in Q2 2026.
What does finance lease principal payments financing activities mean?: Finance Lease Principal Payments Financing Activities as reported by UroGen Pharma Ltd. Ordinary Shares.

Ask your AI about UroGen Pharma's finance lease principal payments financing activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk